About Us

Publications

BMT CTN investigators have published >135 manuscripts, including >30 primary study results papers, in numerous peer-reviewed journals, including the New England Journal of Medicine, Journal of Clinical Oncology, and Blood. Selected publications are summarized for dissemination to patients and the lay public.

Note: Some Publications were unable to be listed below - please see that listing here. All other publications based on PubMedIDs are listed below.

 

Found 139 results
2017
M. Eapen, Kurtzberg, J., Zhang, M. - J., Hattersely, G., Fei, M., Mendizabal, A., Chan, K. Wah, De Oliveira, S., Schultz, K. R., Wall, D., Horowitz, M. M., and Wagner, J. E., “Umbilical Cord Blood Transplantation in Children with Acute Leukemia: Impact of Conditioning on Transplantation Outcomes.”, Biol Blood Marrow Transplant, vol. 23, no. 10, pp. 1714-1721, 2017.
S. A. Holstein, Jung, S. - H., Richardson, P. G., Hofmeister, C. C., Hurd, D. D., Hassoun, H., Giralt, S., Stadtmauer, E. A., Weisdorf, D. J., Vij, R., Moreb, J. S., Callander, N. S., van Besien, K., Gentile, T. G., Isola, L., Maziarz, R. T., Bashey, A., Landau, H., Martin, T., Qazilbash, M. H., Rodriguez, C., McClune, B., Schlossman, R. L., Smith, S. E., Hars, V., Owzar, K., Jiang, C., Boyd, M., Schultz, C., Wilson, M., Hari, P., Pasquini, M. C., Horowitz, M. M., Shea, T. C., Devine, S. M., Linker, C., Anderson, K. C., and McCarthy, P. L., “Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial.”, Lancet Haematol, vol. 4, no. 9, pp. e431-e442, 2017.
2016
J. C. Alvarnas, Le Rademacher, J., Wang, Y., Little, R. F., Akpek, G., Ayala, E., Devine, S., Baiocchi, R., Lozanski, G., Kaplan, L., Noy, A., Popat, U., Hsu, J., Morris, L. E., Thompson, J., Horowitz, M. M., Mendizabal, A., Levine, A., Krishnan, A., Forman, S. J., Navarro, W. H., and Ambinder, R., “Autologous hematopoietic cell transplantation for HIV-related lymphoma: results of the BMT CTN 0803/AMC 071 trial.”, Blood, vol. 128, no. 8, pp. 1050-8, 2016.
“The Blood and Marrow Transplant Clinical Trials Network: An Effective Infrastructure for Addressing Important Issues in Hematopoietic Cell Transplantation.”, Biol Blood Marrow Transplant, vol. 22, no. 10, pp. 1747-1757, 2016.
B. E. Shaw, Lee, S. J., Horowitz, M. M., Wood, W. A., Rizzo, J. D., and Flynn, K. E., “Can we agree on patient-reported outcome measures for assessing hematopoietic cell transplantation patients? A study from the CIBMTR and BMT CTN.”, Bone Marrow Transplant, vol. 51, no. 9, pp. 1173-9, 2016.
P. V. O'Donnell, Eapen, M., Horowitz, M. M., Logan, B. R., DiGilio, A., Brunstein, C., Fuchs, E. J., Flowers, M. E. D., Salit, R., Raj, K., Pagliuca, A., Bradstock, K., Granata, A., Castagna, L., Furst, S., and Blaise, D., “Comparable outcomes with marrow or peripheral blood as stem cell sources for hematopoietic cell transplantation from haploidentical donors after non-ablative conditioning: a matched-pair analysis.”, Bone Marrow Transplant, vol. 51, no. 12, pp. 1599-1601, 2016.
S. J. Lee, Logan, B., Westervelt, P., Cutler, C., Woolfrey, A., Khan, S. P., Waller, E. K., Maziarz, R. T., Wu, J., Shaw, B. E., Confer, D., Horowitz, M. M., and Anasetti, C., “Comparison of Patient-Reported Outcomes in 5-Year Survivors Who Received Bone Marrow vs Peripheral Blood Unrelated Donor Transplantation: Long-term Follow-up of a Randomized Clinical Trial.”, JAMA Oncol, vol. 2, no. 12, pp. 1583-1589, 2016.
J. - A. H. Young, Logan, B. R., Wu, J., Wingard, J. R., Weisdorf, D. J., Mudrick, C., Knust, K., Horowitz, M. M., Confer, D. L., Dubberke, E. R., Pergam, S. A., Marty, F. M., Strasfeld, L. M., Brown, J. Wes M., Langston, A. A., Schuster, M. G., Kaul, D. R., Martin, S. I., and Anasetti, C., “Infections after Transplantation of Bone Marrow or Peripheral Blood Stem Cells from Unrelated Donors.”, Biol Blood Marrow Transplant, vol. 22, no. 2, pp. 359-370, 2016.
J. M. Knight, Syrjala, K. L., Majhail, N. S., Martens, M., Le-Rademacher, J., Logan, B. R., Lee, S. J., Jacobsen, P. B., Wood, W. A., Jim, H. S. L., Wingard, J. R., Horowitz, M. M., Abidi, M. H., Fei, M., Rawls, L., and J Rizzo, D., “Patient-Reported Outcomes and Socioeconomic Status as Predictors of Clinical Outcomes after Hematopoietic Stem Cell Transplantation: A Study from the Blood and Marrow Transplant Clinical Trials Network 0902 Trial.”, Biol Blood Marrow Transplant, vol. 22, no. 12, pp. 2256-2263, 2016.
W. A. Wood, Le-Rademacher, J., Syrjala, K. L., Jim, H., Jacobsen, P. B., Knight, J. M., Abidi, M. H., Wingard, J. R., Majhail, N. S., Geller, N. L., J Rizzo, D., Fei, M., Wu, J., Horowitz, M. M., and Lee, S. J., “Patient-reported physical functioning predicts the success of hematopoietic cell transplantation (BMT CTN 0902).”, Cancer, vol. 122, no. 1, pp. 91-8, 2016.
L. J. Burns, Logan, B. R., Chitphakdithai, P., Miller, J. P., Drexler, R., Spellman, S., Switzer, G. E., Wingard, J. R., Anasetti, C., and Confer, D. L., “Recovery of Unrelated Donors of Peripheral Blood Stem Cells versus Recovery of Unrelated Donors of Bone Marrow: A Prespecified Analysis from the Phase III Blood and Marrow Transplant Clinical Trials Network Protocol 0201.”, Biol Blood Marrow Transplant, vol. 22, no. 6, pp. 1108-1116, 2016.
G. G. Laport, Wu, J., Logan, B., Bachanova, V., Hosing, C., Fenske, T., Longo, W., Devine, S. M., Nademanee, A., Gersten, I., Horowitz, M., Lazarus, H. M., and Riches, M. L., “Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and High-Dose Rituximab for Allogeneic Hematopoietic Cell Transplantation for Follicular Lymphoma: A Phase Two Multicenter Trial from the Blood and Marrow Transplant Clinical Trials Networ”, Biol Blood Marrow Transplant, vol. 22, no. 8, pp. 1440-1448, 2016.
A. Rashidi, DiPersio, J. F., Sandmaier, B. M., Colditz, G. A., and Weisdorf, D. J., “Steroids Versus Steroids Plus Additional Agent in Frontline Treatment of Acute Graft-versus-Host Disease: A Systematic Review and Meta-Analysis of Randomized Trials.”, Biol Blood Marrow Transplant, vol. 22, no. 6, pp. 1133-1137, 2016.
H. S. L. Jim, Sutton, S. K., Small, B. J., Jacobsen, P. B., Wood, W. A., Knight, J. M., Majhail, N. S., Syrjala, K. L., and Lee, S. J., “Trajectories of Quality of Life after Hematopoietic Cell Transplantation: Secondary Analysis of Blood and Marrow Transplant Clinical Trials Network 0902 Data.”, Biol Blood Marrow Transplant, vol. 22, no. 11, pp. 2077-2083, 2016.
S. Shenoy, Eapen, M., Panepinto, J. A., Logan, B. R., Wu, J., Abraham, A., Brochstein, J., Chaudhury, S., Godder, K., Haight, A. E., Kasow, K. A., Leung, K., Andreansky, M., Bhatia, M., Dalal, J., Haines, H., Jaroscak, J., Lazarus, H. M., Levine, J. E., Krishnamurti, L., Margolis, D., Megason, G. C., Yu, L. C., Pulsipher, M. A., Gersten, I., DiFronzo, N., Horowitz, M. M., Walters, M. C., and Kamani, N., “A trial of unrelated donor marrow transplantation for children with severe sickle cell disease.”, Blood, vol. 128, no. 21, pp. 2561-2567, 2016.
F. Ravandi, Othus, M., O'Brien, S. M., Forman, S. J., Ha, C. S., Wong, J. Y. C., Tallman, M. S., Paietta, E., Racevskis, J., Uy, G. L., Horowitz, M., Takebe, N., Little, R., Borate, U., Kebriaei, P., Kingsbury, L., Kantarjian, H. M., Radich, J. P., Erba, H. P., and Appelbaum, F. R., “US Intergroup Study of Chemotherapy Plus Dasatinib and Allogeneic Stem Cell Transplant in Philadelphia Chromosome Positive ALL.”, Blood Adv, vol. 1, no. 3, pp. 250-259, 2016.
W. W. Hope, Walsh, T. J., Goodwin, J., Peloquin, C. A., Howard, A., Kurtzberg, J., Mendizabal, A., Confer, D. L., Bulitta, J., Baden, L. R., Neely, M. N., and Wingard, J. R., “Voriconazole pharmacokinetics following HSCT: results from the BMT CTN 0101 trial.”, J Antimicrob Chemother, vol. 71, no. 8, pp. 2234-40, 2016.
2015
F. R. Appelbaum, Anasetti, C., Antin, J. H., Atkins, H., Davies, S., Devine, S., Giralt, S., Heslop, H., Laport, G., Lee, S. J., Logan, B., Pasquini, M., Pulsipher, M., Stadtmauer, E., Wingard, J. R., and Horowitz, M. M., “Blood and marrow transplant clinical trials network state of the Science Symposium 2014.”, Biol Blood Marrow Transplant, vol. 21, no. 2, pp. 202-24, 2015.
S. G. Holtan, Verneris, M. R., Schultz, K. R., Newell, L. F., Meyers, G., He, F., DeFor, T. E., Vercellotti, G. M., Slungaard, A., MacMillan, M. L., Cooley, S. A., Blazar, B. R., Panoskaltsis-Mortari, A., and Weisdorf, D. J., “Circulating angiogenic factors associated with response and survival in patients with acute graft-versus-host disease: results from Blood and Marrow Transplant Clinical Trials Network 0302 and 0802.”, Biol Blood Marrow Transplant, vol. 21, no. 6, pp. 1029-36, 2015.
N. Khera, Majhail, N. S., Brazauskas, R., Wang, Z., He, N., Aljurf, M. D., Akpek, G., Atsuta, Y., Beattie, S., Bredeson, C. N., Burns, L. J., Dalal, J. D., Freytes, C. O., Gupta, V., Inamoto, Y., Lazarus, H. M., LeMaistre, C. F., Steinberg, A., Szwajcer, D., Wingard, J. R., Wirk, B., Wood, W. A., Joffe, S., Hahn, T. E., Loberiza, F. R., Anasetti, C., Horowitz, M. M., and Lee, S. J., “Comparison of Characteristics and Outcomes of Trial Participants and Nonparticipants: Example of Blood and Marrow Transplant Clinical Trials Network 0201 Trial.”, Biol Blood Marrow Transplant, vol. 21, no. 10, pp. 1815-22, 2015.
P. Anderlini, Wu, J., Gersten, I., Ewell, M., Tolar, J., Antin, J. H., Adams, R., Arai, S., Eames, G., Horwitz, M. E., McCarty, J., Nakamura, R., Pulsipher, M. A., Rowley, S., Leifer, E., Carter, S. L., DiFronzo, N. L., Horowitz, M. M., Confer, D., H Deeg, J., and Eapen, M., “Cyclophosphamide conditioning in patients with severe aplastic anaemia given unrelated marrow transplantation: a phase 1-2 dose de-escalation study.”, Lancet Haematol, vol. 2, no. 9, pp. e367-75, 2015.
S. M. Devine, Owzar, K., Blum, W., Mulkey, F., Stone, R. M., Hsu, J. W., Champlin, R. E., Bin Chen, Y. -, Vij, R., Slack, J., Soiffer, R. J., Larson, R. A., Shea, T. C., Hars, V., Sibley, A. B., Giralt, S., Carter, S., Horowitz, M. M., Linker, C., and Alyea, E. P., “Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncolo”, J Clin Oncol, vol. 33, no. 35, pp. 4167-75, 2015.
J. E. Levine, Braun, T. M., Harris, A. C., Holler, E., Taylor, A., Miller, H., Magenau, J., Weisdorf, D. J., Ho, V. T., Bolaños-Meade, J., Alousi, A. M., and Ferrara, J. L. M., “A prognostic score for acute graft-versus-host disease based on biomarkers: a multicentre study.”, Lancet Haematol, vol. 2, no. 1, pp. e21-9, 2015.
A. C Howard, Fernandez-Vina, M. A., Appelbaum, F. R., Confer, D. L., Devine, S. M., Horowitz, M. M., Mendizabal, A., Laport, G. G., Pasquini, M. C., and Spellman, S. R., “Recommendations for donor human leukocyte antigen assessment and matching for allogeneic stem cell transplantation: consensus opinion of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN).”, Biol Blood Marrow Transplant, vol. 21, no. 1, pp. 4-7, 2015.
M. L. MacMillan, Robin, M., Harris, A. C., DeFor, T. E., Martin, P. J., Alousi, A., Ho, V. T., Bolaños-Meade, J., Ferrara, J. L. M., Jones, R., Arora, M., Blazar, B. R., Holtan, S. G., Jacobsohn, D., Pasquini, M., Socie, G., Antin, J. H., Levine, J. E., and Weisdorf, D. J., “A refined risk score for acute graft-versus-host disease that predicts response to initial therapy, survival, and transplant-related mortality.”, Biol Blood Marrow Transplant, vol. 21, no. 4, pp. 761-7, 2015.